CPT1C silencing drives serosa remodeling, leading to chemotherapy resistance to doxorubicin in BCCs, and the low expression of CPT1C is a predictive marker for poor prognosis in HER2-positive breast cancer and TNBC patients treated with anthracycline-based neoadjuvant chemotherapy.81 Here, CPT1C is linked to breast carcinoma.